Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
2021-02-03 23:45
5408
Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement To Explore Next Generation Immunotherapies With Precision-Targeted T-Cell Engaging Antibodies
- Novel antibody-based cancer immunotherapies to be developed through combining Revitope's dual-antigen precision T-cell engager platform (TEAC) and Junshi Biosciences' antibodies - Revitope to design up to 5 TEAC molecules against tumor targets selected by Junshi Biosciences - For each TEAC mo...
2020-07-14 09:01
6497
